Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.35 |
| ▸ | CBFB | Q13951 | 1/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12649894 | 1.00 | MET (0.42) | METNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL1768972 | 1.00 | MET (0.42) | METNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL1768883 | 0.81 | MET (0.46) | METNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL1769014 | 0.73 | MET (0.41) | METNPC1RAB9ASMN1; SMN2ADORA3 | |
| SCHEMBL6461074 | 0.72 | MET (0.46) | METNPC1RAB9ASMN1; SMN2ADORA3 | |
| SCHEMBL1768941 | 0.71 | ALDH1A1 (0.45) | METNPC1RAB9ASMN1; SMN2ADORA3 | |
| SCHEMBL12649850 | 0.70 | MET (0.49) | METNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL1769206 | 0.69 | MET (0.49) | METNPC1RAB9AADORA3ALDH1A1 | |
| SCHEMBL1768997 | 0.68 | NPC1 (0.49) | NPC1RAB9AMAPTSMN1; SMN2ADORA3 | |
| SCHEMBL1769186 | 0.67 | ALDH1A1 (0.40) | METNPC1RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501700-B1 | Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof | BAYER IP GMBH (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-8604028-B2 | Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| US-20130131055-A1 | FUROPYRIDINYL-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2501700-A1 | FUROPYRIDINYL-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011061157-A1 | FUROPYRIDINYL-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131055-A1 | FUROPYRIDINYL-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | MET, RET, ERBB4 | MET 1/4885NPC1 3871/4885RAB9A 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.